

# Donepezil Market to Reach \$1.1 Billion, Globally, by 2033 at 1.9% CAGR: Allied Market Research

PORTLAND, OR, UNITED STATES,  
December 16, 2024 /

EINPresswire.com/ -- Increasing prevalence of Alzheimer's disease, rise in R&D activities, and increase in government initiatives are the major factors that drive the global market growth.

Allied Market Research published a report, titled, "[Donepezil Market](#) by Dosage Strength (5mg, 10mg and 23mg), Route of Administration (Oral and Transdermal), and Distribution Channel (Hospital Pharmacies, Drug stores and Retail Pharmacies and Online Providers): Global Opportunity Analysis and Industry Forecast, 2024-2033". According to the report, the donepezil market was valued at \$0.9 billion in 2023, and is estimated to reach \$1.1 billion by 2033, growing at a CAGR of 1.9% from 2024 to 2033.



□□□ □ □□□□□□ □□□□ □□ □□□□ □□□□□□: <https://www.alliedmarketresearch.com/request-sample/A324410>

Prime determinants of growth

Increase in prevalence of Alzheimer's disease, rise in R&D activities, and increase in government initiatives are the major factors that drive the growth of the Donepezil market. However, side effects associated with Donepezil may restrict the market growth. Moreover, growth opportunities in emerging markets offer remunerative opportunities for the expansion of the global Donepezil market.

Report coverage & details  
Report Coverage

Details

Forecast Period

2024–2033

Base Year

2023

Market Size in 2023

\$0.9 billion

Market Size in 2033

\$1.1 billion

CAGR

1.9%

No. of Pages in Report

230

Segments Covered

Dosage Strength, Route of Administration, Distribution Channel, and Region.

Drivers

Increasing prevalence of Alzheimer's disease

Rise in R&D activities

Increase in government initiatives

Opportunity

Growth opportunities in emerging markets

Restraint

## Side effects associated with Donepezil

### Segment Highlights

#### Rise in adoption of various Donepezil dosage forms

By dosage strength, the 5 mg segment is driven by its common use in managing mild to moderate Alzheimer's disease. This lower dosage is often preferred for initial treatment or for patients with lower tolerability, providing a balance between efficacy and side effects. As healthcare providers frequently prescribe Donepezil 5 mg to tailor treatment plans, its segment sees significant demand. This trend supports its growth and emphasizes its role in personalized Alzheimer's care.

#### Rise in adoption of oral Donepezil formulations

By route of administration, the oral segment plays an important role in the market. This is attributed to its convenience and ease of use. Oral forms, including tablets and disintegrating tablets, are preferred by both patients and healthcare providers for their non-invasive nature and straightforward administration. This method supports patient compliance and allows for flexible dosing, contributing to its dominance in the market. The simplicity and effectiveness of oral Donepezil formulations enhance their widespread adoption thereby supports the segment growth.

#### Rise in demand for Donepezil in drug stores and retail pharmacies

By distribution channel, the drug stores and retail pharmacies segment held a substantial portion of the Donepezil market share, primarily driven by their widespread accessibility and convenience for patients. These pharmacies often offer personalized services, ensuring patient adherence to medication regimes. In addition, retail pharmacies provide easier access to prescriptions and refills, especially for the elderly population thereby supports the segment growth.

### Regional Outlook

North America is poised to maintain its leadership in the Donepezil market owing to rise in prevalence of Alzheimer's disease, advanced healthcare infrastructure, and significant R&D investments. In addition, benefits from strong government support and policies for Alzheimer's treatment, increasing public awareness, and high healthcare expenditure propels the market growth. Moreover, the presence of key pharmaceutical companies and the availability of advanced drug delivery technologies further solidify North America's dominant position in the Donepezil market.

### Players

Eisai Co., Ltd.□

Alteus

Corium, LLC.□

DD Pharmaceuticals Pvt Ltd

Intas Pharmaceuticals Ltd.

Dr. Reddy's Laboratories Ltd.

Sun Pharmaceutical

Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

Cipla

Alkem

The report provides a detailed analysis of these key players in the global Donepezil market. These players have adopted different strategies such as product approval, acquisition, product launch, and others to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.

#### Recent Developments in Donepezil Industry

In August 2023, Corium, LLC a commercial-stage biopharmaceutical company leading the development and commercialization of novel neuroscience therapies, and Lotus Pharmaceutical a multinational pharmaceutical company, announced that the companies have entered into an exclusive Collaboration and License Agreement for ADLARITY (donepezil transdermal system), an innovative Alzheimer's dementia treatment, in ten markets across Asia.

In October 2022, Corium, LLC and Gurnet Point Capital a private investment firm focused on the healthcare and life sciences sectors announced the acquisition of their manufacturing business and a \$100□million equity investment by Webster Equity Partners a healthcare-focused private equity firm that focuses on applying its expertise in the health care services sector to drive sustainability and long term value. The manufacturing business, named Corium Pharma Solutions, Inc., transacted with an investment by Webster for more than \$400□million in□value.

□□□□□□ □□□□□□ □□□□□□: <https://www.alliedmarketresearch.com/purchase-enquiry/A324410>

David Correa

Allied Market Research

+1 800-792-5285

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/769363095>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.